{{#EntryImageUrl}}
![FDA Permits Expanded Access for Investigational Pancreatic Cancer Drug Daraxonrasib]()
{{/EntryImageUrl}}
FDA Permits Expanded Access for Investigational Pancreatic Cancer Drug Daraxonrasib
Published on May 1, 2026 at 05:35AM by Drugs.com - Daily MedNews
May 01, 2026 -- Today, the U.S. Food and Drug Administration is announcing that it issued a “safe to proceed” letter to Revolution Medicines, allowing the sponsor to initiate an expanded access treatment protocol (EAP) for its...
Read the original article here: https://www.drugs.com/news/fda-permits-expanded-access-investigational-pancreatic-cancer-daraxonrasib-129883.html